scholarly journals Adenoid cystic carcinoma of the breast with distant metastasis to the liver and spleen: a case report

2020 ◽  
Vol 2020 (11) ◽  
Author(s):  
Breanne Gillie ◽  
Michael Kmeid ◽  
Armand Asarian ◽  
Philip Xiao
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Triple Negative ◽  
Treatment Guideline ◽  
Excisional Biopsy ◽  
Breast Cancers ◽  
Palpable Mass ◽  
Adenoid Cystic ◽  
Screening Mammograms ◽  
Low Incidence ◽  
Rare Malignancy

Abstract Adenoid cystic carcinoma (ACC) of the breast is a rare malignancy, accounting for 0.1–1% of breast cancers. Histologically breast ACC is similar to ACC’s found in salivary tissue and is a triple-negative breast cancer with an uncharacteristically favorable prognosis and low incidence of metastasis. Most cases present as a painful, palpable mass; however, asymptomatic cases found on screening mammograms have also been noted. Core needle biopsy or excisional biopsy is necessary for definitive diagnosis of breast ACC. Immunohistochemistry of these cancers can differentiate breast ACC from masses with similar histology, such as invasive cribriform carcinoma and collagenous spherulosis. There is no well-established treatment guideline for ACC; however, it has been noted that reoccurrence and metastasis are noted more in cases of local resection than mastectomy.

scholarly journals Triple-negative apocrine carcinoma as a rare cause of a breast lump in a Syrian female: a case report and review of the literature

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sawsan Ismail ◽  
Haidara Kherbek ◽  
Jana Skef ◽  
Nadim Zahlouk ◽  
Rafik Abdulal ◽  
...  
Keyword(s):  
Case Report ◽  
Triple Negative ◽  
Molecular Subtype ◽  
Excisional Biopsy ◽  
Molecular Characteristics ◽  
Breast Cancers ◽  
Apocrine Carcinoma ◽  
Palpable Mass ◽  
First Case ◽  
Eosinophilic Cytoplasm

Abstract Background Apocrine carcinoma is a rare tumor that constitutes < 4% of all breast malignancies, characterized by the proliferation of large atypical cells with strictly defined borders, abundant eosinophilic cytoplasm, large nuclei, and prominent nucleoli in more than 90% of tumor cells. Triple-negative apocrine carcinoma is a rare molecular subtype that constitutes less than 1% of triple-negative breast cancers and is characterized by negative expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor, with positive expression of androgen receptor. Case presentation We report a case of a 45-year-old Syrian female who presented to our hospital due to a painless palpable mass in her left breast. Following physical and radiological examinations, an excisional biopsy was performed. Microscopic examination of the specimen followed by immunohistochemical staining revealed the diagnosis of a triple-negative apocrine carcinoma. Conclusion Triple-negative apocrine carcinoma is an extremely rare neoplasm that must be considered in the differential diagnoses of breast lesions through detailed clinical, histological, and immunohistochemical correlations. In our manuscript, we aimed to present the first case report of a Syrian female who was diagnosed with a triple-negative apocrine carcinoma, aiming to highlight the importance of detailed clinical, histological and immunohistochemical correlations with a detailed review of diagnostic criteria, molecular characteristics, and treatment recommendations.

Novel treatment options in advanced adenoid cystic carcinoma of the breast.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e13071-e13071
Author(s):  
Evan Wenig ◽  
Reumu E. Birhiray
Keyword(s):  
Disease Control ◽  
Adenoid Cystic Carcinoma ◽  
Metastatic Disease ◽  
Triple Negative ◽  
Treatment Options ◽  
Locally Advanced ◽  
Therapeutic Options ◽  
Breast Mass ◽  
Ongoing Research ◽  
Adenoid Cystic

e13071 Background: Adenoid cystic carcinoma (ACC) accounts for less than 0.1% of all breast cancer cases. The disease typically remains localized and indolent, and frequently occurs with triple negative status. Methods: In patients with locally advanced or metastatic disease, chemotherapy for triple negative breast carcinoma is seldom effective. Thus new treatment paradigms are desired. Drug targeted analysis derived from next generation sequencing and identification of driver mutations may offer a bright future in treatment options in chemo-resistant malignancy. Results: A 53 year old woman presented with breast mass and mastectomy with stage pT3N0M0 triple negative ACC of the breast resulting in observation. She later relapsed with chest wall disease, resulting in resection and radiation therapy. Shortly thereafter, she relapsed with pulmonary metastatic disease. She was treated with carboplatin and doxorubicin which were discontinued due to disease progression. Liquid assay revealed an IDH2 mutation, prompting treatment with enasidenib with ongoing evidence of disease control at 4 months. Patient tolerated treatment well without grade 3 or 4 adverse reactions. A 48 year old woman presented with an increasing 9.5 cm unresectable breast mass without distant metastasis. Pathology showed triple negative ACC of the breast, resulting in chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel with clinically progressive disease. She represented with necrotic and ulcerating changes of the breast. Foundational genomic testing showed an FGFR2 mutation. After four months of treatment with erdafitinib, she had resolution of pain and cessation of pain medication. Her therapy led to a grade 2 adverse event related to hyperphosphatemia. She underwent surgical resection with negative margins. Conclusions: These examples illustrate a potential treatment paradigm for a rare malignancy for which there is no standard of care. Here we present two desperate cases, one of which had a driver mutation of IDH2, and the other FGFR2 for which there are targeted therapies approved in other disease states. The use of these two agents resulted in clinical benefit. A patient with metastatic disease treated with enasidenib has ongoing disease control for over 4 months with minimal adverse reaction. A patient with advanced local disease requiring narcotics and gabapentin for pain control treated with erdafitinib had significant symptomatic control with successful cessation of pain medications and ability to undergo potentially curable mastectomy with negative margins despite progression on prior chemotherapy. In summary, ongoing research of ACC of the breast will be required. Alternative therapeutic options related to targeted treatment may offer promise to clinical outcomes in the future. For cases of locally advanced or metastatic disease, the use of targeted therapy may offer new therapeutic options.

scholarly journals Case Report: Efficacy of Pyrotinib in ERBB2 Amplification Pulmonary Adenoid Cystic Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Zhongben Tang ◽  
Feng Lin ◽  
Jiarong Xiao ◽  
Xiaojun Du ◽  
Jian Zhang ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Adenoid Cystic Carcinoma ◽  
Large Scale ◽  
Case Reports ◽  
Growth Factor Receptor ◽  
Low Grade ◽  
Adenoid Cystic ◽  
Epidermal Growth ◽  
Low Incidence ◽  
Current Report

Primary pulmonary adenoid cystic carcinomas are salivary tumors that are low-grade malignant and prone to recurrence and metastasis. Surgery is currently the main treatment, but there is no standard with regard to postoperative adjuvant therapy. Adenoid cystic carcinoma is more sensitive to radiotherapy and patients benefit less from chemotherapy, but few studies have focused on targeted therapy, and their conclusions are inconsistent. With respect to primary pulmonary adenoid cystic carcinoma, large-scale studies cannot be conducted due to its low incidence, and studies on the targeted therapy of it are very scarce. A few case reports indicate that targeted therapy can be effective however, suggesting that it may be a good option. The current report is the first on the occurrence of human epidermal growth factor receptor 2 amplification in pulmonary adenoid cystic carcinoma. The patient was treated with pyrotinib for 6 months and achieved stable disease.

scholarly journals Adenoid cystic carcinoma of the breast: case report

Mastology ◽  
2021 ◽  
Vol 31 ◽  
Author(s):  
Matheus Lavigne Marinho ◽  
Alexandre Tafuri ◽  
Carlos Alberto da Silva Ramos ◽  
Antônio Alexandre Lisbôa Ladeia ◽  
Luciana de Carvalho Azevedo
Keyword(s):  
Breast Cancer ◽  
Adenoid Cystic Carcinoma ◽  
Triple Negative ◽  
Breast Conserving Surgery ◽  
Genetic Alterations ◽  
Good Prognosis ◽  
Carcinoma Of The Breast ◽  
Adenoid Cystic ◽  
Molecular Aspects ◽  
Peculiar Behavior

Adenoid cystic carcinoma (AdCC) of the breast is an uncommon invasive lobular neoplasm whose morphology is similar to the homonymous tumor of salivary glands and with a peculiar behavior toward the “triple-negative” (TN) profile. Tumors belonging to this family do not immunohistochemically express three of the main prognostic biomarkers and tend to show a more aggressive behavior. However, this rare histological pattern of breast cancer is generally associated with good prognosis. In this study, the authors describe the case of a 49-year-old woman diagnosed with this rare malignant tumor and who underwent breast-conserving surgery. Recent studies have aimed to understand the genes, genetic alterations, and etiological aspects related to the still obscure etiopathogenesis of AdCC. Thus, morphological and molecular aspects relevant to AdCC and reported in the literature will be discussed.

scholarly journals Two Different Cell Populations Is an Important Clue for Diagnosis of Primary Cutaneous Adenoid Cystic Carcinoma: Immunohistochemical Study

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Banu Ince Alkan ◽  
Onder Bozdogan ◽  
Müjde Karadeniz ◽  
Nazan Bozdoğan
Keyword(s):  
Differential Diagnosis ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Immunohistochemical Study ◽  
Cell Populations ◽  
Metastatic Lesions ◽  
Adenoid Cystic ◽  
Rare Malignancy ◽  
Immunohistochemical Studies

Primary cutaneous adenoid cystic carcinoma (PCACC) is a very rare malignancy. The differential diagnosis of PCACCs in pathology practice can be difficult and a group of primary and metastatic lesions, including adenoid basal cell carcinoma of the skin, should be considered in the differential diagnosis. Besides histomorphological clues, immunohistochemistry studies are very helpful in the differential diagnosis of PCACC. We report herein a case of PCACC with extensive immunohistochemical studies and review the literature from an immunohistochemistry perspective.

scholarly journals In vitro and in vivo evaluation of cytotoxic effect of targeted agents alone or in combination with chemotherapy for the treatment of adenoid cystic carcinoma

2021 ◽  
Author(s):  
Teresa Savarese ◽  
Andrea Abate ◽  
Ram Manohar Basnet ◽  
Luigi Lorini ◽  
Cristina Gurizzan ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Adenoid Cystic Carcinoma ◽  
Standard Chemotherapy ◽  
In Vivo Evaluation ◽  
Cytotoxic Effects ◽  
Chemotherapy Drugs ◽  
Adenoid Cystic ◽  
Rare Malignancy

Abstract Purpose Adenoid cystic carcinoma (ACC) is a rare malignancy characterized by high incidence of relapse. When relapsing, ACC has an indolent but relentless behaviour, thus leading to a poor long-term prognosis. The treatment of choice of relapsing ACC remains surgery followed by radiotherapy, whenever feasible. Therapeutic weapons are limited to systemic drugs. The most widely used chemotherapy regimen is the combination of cisplatin and doxorubicin, however with low response rate and not long lasting; there is also a lack of alternatives for second line therapies in case of disease progression. Therefore, a more comprehensive strategy aimed at identifying at preclinical level the most promising drugs or combination is clearly needed. Methods In this study, the cytotoxic effects of two standard chemotherapy drugs, cisplatin and doxorubicin, and of five targeted therapy-drugs was tested in vitro, on an h-TERT immortalized ACC cell line. The same drugs were also tested in vivo, on zebrafish embryos with ACC tumoral cell xenograft. Then, combinations of one standard chemotherapy drug plus one targeted therapy drug were also evaluated, in order to find the best treatment strategy for ACC. Results Data obtained demonstrated that both vorinostat and olaparib significantly increased the standard chemotherapy cytotoxic effects, suggesting new interesting therapeutic options for ACC. Conclusion Data obtained in the present study provide valid new therapeutic strategies for ACC to be translated in a prospective clinical trial.

scholarly journals Metastatic Adenoid Cystic Carcinoma of Prostate: Is Androgen Deprivation Therapy Beneficial?

2014 ◽  
Vol 48 (1) ◽  
pp. 43-45
Author(s):  
Amanjit Bal ◽  
Shrawan K Singh ◽  
Madhusudhanan Gnanasekharan ◽  
Raguram Ganesamoni
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Androgen Deprivation Therapy ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Palliative Radiotherapy ◽  
Androgen Deprivation ◽  
Transurethral Resection Of Prostate ◽  
Basal Cells ◽  
Adenoid Cystic ◽  
Rare Malignancy

ABSTRACT Adenoid cystic carcinoma of prostate is a rare malignancy arising from basal cells of prostatic acini. The management of metastatic adenoid cystic carcinoma of prostate is not well defined because of its rarity. We report a 68-year-old male presented with acute urinary retention and pain in left hip region. Digital rectal examination revealed a hard nodular prostate with extension to the lateral pelvic walls. His serum PSA was 0.15 ng/ml. Transrectal ultrasound (TRUS) guided prostate biopsy revealed adenoid cystic carcinoma. Bone scan showed metastasis in left acetabulum. He underwent channel transurethral resection of prostate and bilateral orchiectomy. He received palliative radiotherapy for left acetabular metastasis to control his pain. At 3 years of follow-up, the patient is doing well with no new metastasis. Hormone therapy is a viable option in patients with metastatic adenoid cystic carcinoma of prostate. How to cite this article Singh SK, Gnanasekharan M, Kumar S, Ganesamoni R, Bal A. Metastatic Adenoid Cystic Carcinoma of Prostate: Is Androgen Deprivation Therapy Beneficial. J Postgrad Med Edu Res 2014;48(1):43-45.

scholarly journals Adenoid cystic carcinoma of the Bartholin's gland: the University of Michigan experience

1994 ◽  
Vol 4 (3) ◽  
pp. 145-149 ◽  
Author(s):  
R. J. Lelle ◽  
K. P. Davis ◽  
J. A. Roberts
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Medical Center ◽  
Excisional Biopsy ◽  
Distant Recurrence ◽  
High Recurrence Rate ◽  
University Of Michigan ◽  
Presenting Symptoms ◽  
Adenoid Cystic ◽  
Bartholin’S Gland ◽  
The University

Adenoid cystic carcinoma of the Bartholin's gland has been encountered in 11 patients at the University of Michigan Medical Center since 1936. At the time of presentation the average age was 48.9 years, the lesion size was between 0.5 to 4 cm. The presenting symptoms were pain and/or pruritis associated with a solitary mass. Early in this series, excisional biopsy was used to treat eight patients. The last three patients have been treated with a radical vulvectomy and unilateral or bilateral groin lymph node dissection. Local recurrence has occurred in five patients and distant recurrence in four patients. In spite of the high recurrence rate, 5- and 10-year survival has been high with all seven evaluable patients surviving 5 and 10 years. However, adenoid cystic carcinoma of the vulva is associated with late recurrences and metastases: three patients were dead of disease at 12, 15 and 31 years after initial diagnosis.

Sign in / Sign up

Export Citation Format

Share Document